SecBot SecBot
Biotech Drug Report Generated Aug 21, 2026

Diovan

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating1/10
Trial phase
Approved (genericized / off-patent legacy brand)
Time to market
Already approved and long off-patent; the brand is superseded by generic valsartan from multiple manufacturers.
Why 1/10
No hard, dated catalyst is scheduled in the next ~12 months: Diovan/valsartan is a fully genericized, off-patent molecule with no Novartis-sponsored development, no pending FDA decision, and no catalyst records, the defining binaries (original approval and the patent cliff) passed years ago, so the drug can drive essentially no share-price move at a mega-cap like NVS.
Actionable Insight NEUTRAL

There is nothing to trade on Diovan itself, it is a generic commodity now. Investors watching Novartis should ignore this molecule and instead track the cardiovascular franchise via the sacubitril/valsartan combination (a separate product) plus pending pipeline readouts (e.g., BION-1301, iptacopan) that actually move NVS. Current NVS setup: price ~$156.24, analyst recommendation "hold" with mean target $157.15 (implied upside ~2.5%).

Price Chart

Loading chart...

Executive Summary

Diovan (valsartan) is Novartis's once-blockbuster blood-pressure medicine, now a fully genericized legacy brand: the FDA action records in this session show only generic manufacturers (Ohm Laboratories, Umedica Laboratories) actively labeling valsartan and valsartan-combination products in 2026, and no FDA catalyst, press release, or Novartis-sponsored trial exists for the drug. At a ~$156 stock with a "hold" consensus and a pipeline focused on newer drugs, Diovan is immaterial to NVS's valuation.

How It Works

Valsartan is an angiotensin II receptor blocker (ARB): it blocks a hormone that constricts blood vessels, letting them relax and lowering blood pressure. It was a once-blockbuster Novartis blood-pressure pill (Diovan), but the molecule is now off-patent and sold as cheap generics.

Trial Status

No Novartis-sponsored trials for Diovan/valsartan appear in the local pipeline data; the molecule shows up only as generic valsartan used as comparator/background therapy in hypertension studies (e.g., NCT07700875, valsartan 160 mg in essential hypertension) or inside the separate sacubitril/valsartan combination product. FDA records show only routine safety-labeling updates (fetal-toxicity boxed warning) from generic ANDA holders Ohm Laboratories (ANDA077492) and Umedica Laboratories (ANDA219946) dated July–August 2026.

The Two-Sided Case

▲ Bull Case2
Valsartan remains a standard-of-care blood-pressure agent with entrenched clinical use: FDA records show the molecule still being actively labeled (pharm class: Angiotensin 2 Receptor Blocker) with July–August 2026 safety-labeling updates, and it continues to appear as an active comparator in hypertension trials (NCT07700875).
The molecule's clinical franchise lives on inside Novartis's cardiovascular portfolio through the sacubitril/valsartan combination (a distinct product), which still shows up in Phase 2/3 trials mapped to NVS in the local pipeline data, a modest franchise halo, not a Diovan catalyst.
▼ Bear Case3
Fully genericized: every recent FDA action row for valsartan is a generic Abbreviated New Drug Application holder (Ohm Laboratories ANDA077492; Umedica Laboratories ANDA219946 for sacubitril/valsartan), not the branded Diovan, no proprietary brand economics remain.
Zero scheduled catalysts: no FDA catalyst rows, no catalyst-outcome history, no press releases, and no Novartis-sponsored trials for Diovan/valsartan in this session's data, there is no binary event to trade.
Immaterial to the stock: NVS is a mega-cap trading at ~$156.24 with a 'hold' analyst consensus (mean price target $157.15, implied upside ~2.5% per local consensus data); Diovan is not part of the investment thesis and cannot move the share price.

Upcoming Catalysts

  • None for Diovan/valsartan, no regulatory or clinical events scheduled.
  • Context for NVS shareholders (not Diovan): results-pending readouts flagged in local data include BION-1301 (Phase 2 IgA nephropathy) and iptacopan (Phase 3 aHUS); NVS also carries elevated FINRA short-volume flow (~55–58% short ratio on recent off-exchange sessions).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov